Bicycle Therapeutics shares fall 23% after the company shares interim Phase 1 data

Bicycle Therapeutics shares fall 23% after the company shares interim Phase 1 data

Submitted by admin on April 11, 2022 - 10:39am
Source: 
Marketwatch
News Tags: 
AACR
Bicycle Therapeutics
clinical trials
urothelial cancer
BT8009
Headline: 
Bicycle Therapeutics shares fall 23% after the company shares interim Phase 1 data
snippet: 

Shares of Bicycle Therapeutics Inc. BCYC, -30.10% tumbled 23.4% in premarket trading on Monday after the company shared interim data from a Phase 1 clinical trial for its urothelial-cancer treatment. 

Do Not Allow Advertisers to Use My Personal information